We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK politicians could go public with the price of Vertex’s cystic fibrosis drug Orkambi, if the company does not strike a deal giving NHS patients access by the end of the month.